Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Talzenna Neoplasm	Pfizer	P3	B (59)
Carboplatin Colorectal Neoplasm	Pfizer	P2	B (59)
Fludarabine Non-small Cell Lung Cancer, Squamous	Pfizer	P2	B (59)
Metformin Sickle Cell Disease	Pfizer	P2	B (59)
Binimetinib Neoplasm	Pfizer	P4	B (58)
Encorafenib Neoplasm	Pfizer	P4	B (58)
Cytosin-Arabinosid Non-Small Cell Lung Cancer	Pfizer	P3	B (58)
Daunorubicin Non-Small Cell Lung Cancer	Pfizer	P3	B (58)
ETOPOSIDE Hepatocellular Carcinoma	Pfizer	P3	B (58)
ETOPOSIDE Lung Neoplasm	Pfizer	P3	B (58)
met097 Obesity Disorder	Pfizer	P3	B (58)
pf-08653944 Obesity Disorder	Pfizer	P3	B (58)
Talzenna Breast Neoplasm	Pfizer	P3	B (58)
Hycamtin Ewing Sarcoma	Pfizer	P2	B (58)
pf-08634404 Hepatocellular Carcinoma	Pfizer	P2	B (58)
rc48-adc Breast Neoplasm	Pfizer	P2/3	B (58)
Cmp 001 Urothelial Carcinoma	Pfizer	P3	B (57)
IMMUNOGLOBULIN G1, ANTI-(HUMAN TISSUE FACTOR PATHWAY INHIBITOR) (HUMAN MONOCLONAL PF-06741086 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PF-06741086 .LAMBDA.-CHAIN, DIMER Hemophilia A	Pfizer	P3	B (57)
Ivuxolimab Urothelial Carcinoma	Pfizer	P3	B (57)
Lorlatanib Urothelial Carcinoma	Pfizer	P3	B (57)
pf-08634404 Digestive System Neoplasm	Pfizer	P3	B (57)
Benadryl BCMA	Pfizer	P2	B (57)
Benadryl BCMA-CD3 Bispecific	Pfizer	P2	B (57)
Benadryl Bispecific	Pfizer	P2	B (57)
Benadryl Bispecific Antibody	Pfizer	P2	B (57)

Showing 101 to 125 of 461 assets